| Title: |
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021 |
| Authors: |
Tenforde, Mark W; Self, Wesley H; Naioti, Eric A; Ginde, Adit A; Douin, David J; Olson, Samantha M; Talbot, H Keipp; Casey, Jonathan D; Mohr, Nicholas M; Zepeski, Anne; Gaglani, Manjusha; McNeal, Tresa; Ghamande, Shekhar; Shapiro, Nathan I; Gibbs, Kevin W; Files, D Clark; Hager, David N; Shehu, Arber; Prekker, Matthew E; Erickson, Heidi L; Gong, Michelle N; Mohamed, Amira; Henning, Daniel J; Steingrub, Jay S; Peltan, Ithan D; Brown, Samuel M; Martin, Emily T; Monto, Arnold S; Khan, Akram; Hough, Catherine L; Busse, Laurence W; Lohuis, Caitlin C ten; Duggal, Abhijit; Wilson, Jennifer G; Gordon, Alexandra June; Qadir, Nida; Chang, Steven Y; Mallow, Christopher; Rivas, Carolina; Babcock, Hilary M; Kwon, Jennie H; Exline, Matthew C; Halasa, Natasha; Chappell, James D; Lauring, Adam S; Grijalva, Carlos G; Rice, Todd W; Jones, Ian D; Stubblefield, William B; Baughman, Adrienne; Womack, Kelsey N; Lindsell, Christopher J; Hart, Kimberly W; Zhu, Yuwei; Stephenson, Meagan; Schrag, Stephanie J; Kobayashi, Miwako; Verani, Jennifer R; Patel, Manish M; Investigators, IVY Network; Network, IVY; Calhoun, Nicole; Murthy, Kempapura; Herrick, Judy; McKillop, Amanda; Hoffman, Eric; Zayed, Martha; Smith, Michael; Settele, Natalie; Ettlinger, Jason; Priest, Elisa; Thomas, Jennifer; Arroliga, Alejandro; Beeram, Madhava; Kindle, Ryan; Kozikowski, Lori-Ann; De Souza, Lesley; Ouellette, Scott; Thornton-Thompson, Sherell; Tyler, Patrick; Mehkri, Omar; Ashok, Kiran; Gole, Susan; King, Alexander; Poynter, Bryan; Stanley, Nicholas; Hendrickson, Audrey; Maruggi, Ellen; Scharber, Tyler; Jorgensen, Jeffrey; Bowers, Robert; King, Jennifer; Aston, Valerie; Armbruster, Brent; Rothman, Richard E; Nair, Rahul; Chen, Jen-Ting; Karow, Sarah; Robart, Emily; Maldonado, Paulo Nunes |
| Source: |
MMWR Morbidity and Mortality Weekly Report, vol 70, iss 34 |
| Publisher Information: |
eScholarship, University of California |
| Publication Year: |
2021 |
| Collection: |
University of California: eScholarship |
| Subject Terms: |
32 Biomedical and Clinical Sciences (for-2020); 3202 Clinical Sciences (for-2020); Immunization (rcdc); Coronaviruses Disparities and At-Risk Populations (rcdc); Coronaviruses (rcdc); Infectious Diseases (rcdc); Emerging Infectious Diseases (rcdc); Biotechnology (rcdc); Clinical Research (rcdc); Coronaviruses Vaccines (rcdc); Vaccine Related (rcdc); Prevention (rcdc); 3.4 Vaccines (hrcs-rac); Infection (hrcs-hc); 3 Good Health and Well Being (sdg); Adolescent (mesh); Adult (mesh); Aged (mesh); COVID-19 (mesh); COVID-19 Vaccines (mesh); Female (mesh); Hospitalization (mesh); Humans (mesh); Male (mesh); Middle Aged (mesh); Time Factors (mesh); United States (mesh); Vaccination (mesh); Vaccines; Synthetic (mesh) |
| Time: |
1156 - 1162 |
| Description: |
Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability of protection. In an evaluation at 21 hospitals in 18 states, the duration of mRNA vaccine (Pfizer-BioNTech or Moderna) effectiveness (VE) against COVID-19-associated hospitalizations was assessed among adults aged ≥18 years. Among 3,089 hospitalized adults (including 1,194 COVID-19 case-patients and 1,895 non-COVID-19 control-patients), the median age was 59 years, 48.7% were female, and 21.1% had an immunocompromising condition. Overall, 141 (11.8%) case-patients and 988 (52.1%) controls were fully vaccinated (defined as receipt of the second dose of Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines ≥14 days before illness onset), with a median interval of 65 days (range=14-166 days) after receipt of second dose. VE against COVID-19-associated hospitalization during the full surveillance period was 86% (95% confidence interval [CI]=82%-88%) overall and 90% (95% CI=87%-92%) among adults without immunocompromising conditions. VE against COVID-19- associated hospitalization was 86% (95% CI=82%-90%) 2-12 weeks and 84% (95% CI=77%-90%) 13-24 weeks from receipt of the second vaccine dose, with no significant change between these periods (p = 0.854). Whole genome sequencing of 454 case-patient specimens found that 242 (53.3%) belonged to the B.1.1.7 (Alpha) lineage and 74 (16.3%) to the B.1.617.2 (Delta) lineage. Effectiveness of mRNA vaccines against COVID-19-associated hospitalization was sustained over a 24-week period, including among groups at higher risk for severe COVID-19; ongoing monitoring is needed as new SARS-CoV-2 variants emerge. To reduce their risk for hospitalization, all eligible persons should be offered COVID-19 vaccination. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
unknown |
| Relation: |
qt584662bk; https://escholarship.org/uc/item/584662bk; https://escholarship.org/content/qt584662bk/qt584662bk.pdf |
| DOI: |
10.15585/mmwr.mm7034e2 |
| Availability: |
https://escholarship.org/uc/item/584662bk; https://escholarship.org/content/qt584662bk/qt584662bk.pdf; https://doi.org/10.15585/mmwr.mm7034e2 |
| Rights: |
public |
| Accession Number: |
edsbas.BAD9FF24 |
| Database: |
BASE |